ReproCELL
Private Company
Total funding raised: $28M
Overview
ReproCELL is a UK-based, privately-held life sciences company founded in 2003, operating at the intersection of stem cell technology, drug discovery, and precision medicine. It has evolved from a stem cell product supplier into an integrated global provider of research tools, GMP-compliant cell manufacturing, and human tissue-based preclinical contract research services. The company leverages strategic acquisitions to build a diversified portfolio that supports the entire drug development pipeline, from discovery through to clinical-stage cell therapy manufacturing. Its focus on human-derived models and regulatory-compliant services positions it as a key enabler for translational research.
Technology Platform
Integrated ecosystem including StemRNA™ iPSC reprogramming, Alvetex® 3D tissue engineering, StemEdit (OpenCRISPR-1™) AI-driven gene editing, GMP cell manufacturing, and human tissue-based ex vivo testing.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
ReproCELL competes in fragmented but competitive segments. In stem cell products, it faces firms like Thermo Fisher Scientific and Fujifilm Cellular Dynamics. In 3D cell culture, competitors include Corning and Emulate. In CRO services, it competes with large players like LabCorp and Charles River, as well as specialized human tissue CROs. Its integrated, end-to-end model across these areas is a key differentiator.